Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
4.60
Dollar change
+0.24
Percentage change
5.50
%
Index- P/E- EPS (ttm)-5.71 Insider Own6.77% Shs Outstand59.74M Perf Week-1.29%
Market Cap274.80M Forward P/E- EPS next Y-1.00 Insider Trans0.00% Shs Float55.70M Perf Month-9.27%
Income-99.95M PEG- EPS next Q-0.32 Inst Own36.86% Short Float1.31% Perf Quarter86.23%
Sales0.00M P/S- EPS this Y51.83% Inst Trans150.31% Short Ratio1.79 Perf Half Y65.47%
Book/sh1.85 P/B2.49 EPS next Y-26.16% ROA-94.90% Short Interest0.73M Perf Year259.38%
Cash/sh1.31 P/C3.51 EPS next 5Y- ROE-119.41% 52W Range1.23 - 5.54 Perf YTD155.56%
Dividend Est.- P/FCF- EPS past 5Y29.97% ROI-130.87% 52W High-16.97% Beta0.76
Dividend TTM- Quick Ratio6.53 Sales past 5Y0.00% Gross Margin- 52W Low273.95% ATR (14)0.40
Dividend Ex-Date- Current Ratio6.53 EPS Y/Y TTM24.21% Oper. Margin- RSI (14)57.51 Volatility11.42% 8.75%
Employees20 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price13.88
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q8.63% Payout- Rel Volume2.00 Prev Close4.36
Sales Surprise- EPS Surprise-1.59% Sales Q/Q- EarningsNov 12 AMC Avg Volume409.47K Price4.60
SMA206.16% SMA5023.00% SMA20067.78% Trades Volume820,972 Change5.50%
Date Action Analyst Rating Change Price Target Change
May-13-22Resumed Cantor Fitzgerald Overweight $25 → $15
Mar-23-21Initiated Cantor Fitzgerald Overweight $25
Nov-12-24 04:01PM
Nov-06-24 04:05PM
Oct-29-24 07:46AM
07:45AM
Sep-11-24 04:05PM
07:00AM Loading…
Sep-04-24 07:00AM
Aug-14-24 05:21PM
Jul-29-24 07:00AM
Jul-02-24 04:05PM
Jun-17-24 09:36AM
Jun-11-24 03:18PM
Jun-03-24 04:01PM
May-27-24 09:55AM
May-22-24 12:00PM
May-14-24 12:00PM
01:54PM Loading…
May-09-24 01:54PM
07:30AM
07:00AM
May-07-24 07:05AM
07:00AM
Mar-28-24 04:01PM
Mar-25-24 04:56PM
Mar-21-24 10:31AM
Feb-13-24 07:01PM
Jan-04-24 04:40PM
Dec-04-23 06:00PM
Nov-29-23 04:05PM
Nov-09-23 04:01PM
Nov-08-23 04:05PM
Nov-02-23 09:05AM
07:00AM Loading…
Oct-23-23 07:00AM
Oct-13-23 07:00AM
Oct-02-23 07:00AM
Sep-25-23 07:00AM
Sep-20-23 04:05PM
Sep-11-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-16-23 07:00AM
Aug-10-23 07:00AM
Jul-12-23 07:30AM
Jun-02-23 08:00AM
May-11-23 04:01PM
May-04-23 04:05PM
May-01-23 07:00AM
Apr-05-23 07:46PM
Mar-31-23 06:00AM
Mar-30-23 04:01PM
Mar-23-23 04:05PM
08:00AM
Feb-08-23 04:05PM
Jan-09-23 08:31AM
08:30AM
Dec-21-22 04:05PM
Nov-14-22 04:01PM
Nov-03-22 04:05PM
Oct-24-22 04:05PM
Oct-03-22 08:00AM
Sep-22-22 04:05PM
Sep-06-22 04:01PM
Aug-29-22 08:00AM
Aug-11-22 04:01PM
Aug-04-22 04:05PM
Aug-01-22 05:00AM
Jul-18-22 08:00AM
Jun-10-22 04:05PM
Jun-09-22 08:00AM
Jun-02-22 04:05PM
12:01PM
May-31-22 06:00AM
May-12-22 04:01PM
May-09-22 08:00AM
May-05-22 04:05PM
May-03-22 04:05PM
Apr-18-22 04:05PM
Apr-14-22 04:05PM
Mar-24-22 04:01PM
12:58PM
Mar-17-22 08:00AM
Feb-14-22 08:00AM
Feb-08-22 04:05PM
Jan-13-22 10:08AM
Dec-27-21 05:17PM
Dec-24-21 06:22AM
Nov-11-21 04:05PM
Nov-04-21 05:34PM
04:05PM
Nov-01-21 08:00AM
Oct-19-21 07:00AM
Oct-07-21 07:51AM
Oct-05-21 04:22PM
Sep-01-21 04:05PM
Aug-12-21 04:01PM
Aug-02-21 08:05AM
Jul-26-21 08:00AM
Jul-02-21 08:00AM
Jun-29-21 04:07PM
Jun-27-21 05:01AM
May-18-21 08:00AM
May-13-21 04:01PM
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.